WEST HAVEN — Biochemical company NanoViricides has received a fundamental patent for its anti-virus technology, which will last through 2026.

The US Patent (No. 8,173,764) for “Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers” is for the tiny molecules the company has developed intended to combat viruses including influenza, hepatitis and HIV by tricking the virus into landing on artificial host cells that will then destroy the virus.

The patent will be in effect through October 1, 2026, and may be extended.